ACBC-containing model peptides adopted characteristic stable conformations that could improve peptide drug stability and oral bioavailability.
Conformational constraintACBC residues forced peptides into predictable stable conformations — helical or extended — that resist degradation
What the researchers found
ACBC-containing model peptides adopted characteristic stable conformations (helical and extended) that could be leveraged for peptide drug design.
Why it matters
One of the biggest challenges in peptide drug development is that peptides are floppy and easily broken down. Constrained building blocks like ACBC help solve both problems by locking peptides into stable, active shapes.
How the study worked
Molecular mechanics calculations on model peptides containing ACBC and its derivatives to determine low-energy conformations and compare them to natural amino acid peptides.
What this study cannot tell us
Computational modeling study without experimental validation. Predicted conformations need to be confirmed by actual structural studies like NMR or X-ray crystallography.
How to read the evidence
Preliminary — computational study without experimental validation. Predicted conformations need structural confirmation.
When this study was published
Published in 1995 (31 years ago). Constrained peptidomimetics have since become a major area of drug design.
The bigger picture
Making peptides that survive digestion and can be taken as pills is a holy grail of drug development. Constrained building blocks like ACBC help solve this by making peptides resistant to enzymatic breakdown.
Questions still open
- Have ACBC-containing peptides been validated experimentally?
- Can this approach be applied to opioid peptide drug design?
Common questions
Why are peptide drugs hard to take as pills?
What is a peptidomimetic?
Read the original research
Conformational studies on model peptides with 1-aminocyclobutane 1-carboxylic acid residues.
Peptide research, 8(3), 178-86
Citation
Balaji, V N; Ramnarayan, K; Chan, M F; Rao, S N. (1995). Conformational studies on model peptides with 1-aminocyclobutane 1-carboxylic acid residues.. Peptide research, 8(3), 178-86.